Sunflower Pharmaceutical's 2026 interim net profit was 79.4695 million yuan, down 2.26% year-on-year

Jiemian··CN·Read original
2▲0 ▼1Impact / 5
Summary · why it matters

Sunflower Pharmaceutical released its 2026 interim report. Total operating revenue was 1.498 billion yuan, and net profit attributable to the parent company was 79.4695 million yuan, down 2.26% from the same period last year. Net cash inflow from operating activities was 25.548 million yuan, down 92.69% year-on-year. The company's asset-liability ratio was 23.16%, gross margin was 54.92%, and diluted earnings per share was 0.14 yuan. The number of shareholders was 44,400, and the top ten shareholders held 60.36% of the total share capital.

Impact on assets 1

Others▼ · 1 stocks
© 2026 MarketIVNews